NCR2
Natural cytotoxicity triggering receptor 2
Also known as: CD336, LY95, NCTR2_HUMAN, NK-p44
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O95944
- Gene
- NCR2
- Ensembl
- ENSG00000096264
- Chromosome
- 6
- Canonical length
- 276 aa
- Protein class
- CD markers, Predicted membrane proteins
OverviewNCBI Gene
Predicted to enable signaling receptor activity. Predicted to be involved in cellular defense response and signal transduction. Predicted to be located in plasma membrane. Predicted to be active in cell surface. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
276 residues, UniProt reviewed canonical sequence.
>O95944|NCR2
1 MAWRALHPLL LLLLLFPGSQ AQSKAQVLQS VAGQTLTVRC QYPPTGSLYE KKGWCKEASA
61 LVCIRLVTSS KPRTMAWTSR FTIWDDPDAG FFTVTMTDLR EEDSGHYWCR IYRPSDNSVS
121 KSVRFYLVVS PASASTQTSW TPRDLVSSQT QTQSCVPPTA GARQAPESPS TIPVPSQPQN
181 STLRPGPAAP IALVPVFCGL LVAKSLVLSA LLVWWGDIWW KTMMELRSLD TQKATCHLQQ
241 VTDLPWTSVS SPVEREILYH TVARTKISDD DDEHTLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NCR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 0.4 nTPM
Expression across tissuesHPA
Tissue
- duodenum: 0.4 nTPM
- tonsil: 0.3 nTPM
- rectum: 0.2 nTPM
- small intestine: 0.2 nTPM
- thymus: 0.2 nTPM
- spleen: 0.1 nTPM
Single-cell type
- nk-cells: 11 nCPM
- innate lymphoid cells: 8.8 nCPM
- adipocytes: 1.9 nCPM
- pdcs: 1.9 nCPM
- thymocytes: 1.7 nCPM
- neuroendocrine cells: 1.4 nCPM
Immune cell
- plasmacytoid DC: 4.9 nTPM
- NK-cell: 1.7 nTPM
- MAIT T-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- cerebral cortex: 1.3 nTPM
- medulla oblongata: 0.8 nTPM
- basal ganglia: 0.6 nTPM
- pons: 0.6 nTPM
- spinal cord: 0.4 nTPM
- hippocampal formation: 0.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.44
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.19
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NCR2 as an antibody target. Whether an autoantibody or antibody against NCR2 could matter depends on whether native NCR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NCR2 is annotated at the cell surface, where native NCR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label NCR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...